Integrated BioTherapeutics (IBT) announced today that it has entered into an exclusive worldwide license agreement with Emergent BioSolutions Inc. (NYSE: EBS) whereby Emergent will gain exclusive rights to use IBT's proprietary vaccine antigens and know-how in a joint research, development, and manufacturing collaboration focused on an equine-based hyperimmunoglobulin for the treatment of hemorrhagic fever caused by Filoviruses. Financial terms of the agreement are not disclosed.